Ripisartan

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328027

CAS#: 148504-51-2

Description: Ripisartan, also known as UP-269-6, is a potent and specific angiotensin II receptor antagonist and dose not possess agonistic properties. UP 269-6 antagonized the angiotensin II sympathetic-mediated tachycardiac response. UP 269-6 inhibited dose dependently the pressor response to angiotensin II with an ID50 of 4.5 micrograms/kg, i.v. in conscious normotensive dogs.

Chemical Structure

img
Ripisartan
CAS# 148504-51-2
Instruction

Theoretical Analysis

MedKoo Cat#: 328027
Name: Ripisartan
CAS#: 148504-51-2
Chemical Formula: C23H22N8O
Exact Mass: 426.19
Molecular Weight: 426.484
Elemental Analysis: C, 64.77; H, 5.20; N, 26.27; O, 3.75

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ripisartan; UP-269-6; UP 269-6; UP269-6; UP-2696; UP 2696; UP2696.

IUPAC/Chemical Name: 5-Methyl-7-propyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-(1,2,4)triazolo(1,5-c)pyrimidin-2(3H)-one

InChi Key: OLJAPHMBAMBVKL-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H22N8O/c1-3-6-20-19(22-25-23(32)28-31(22)14(2)24-20)13-15-9-11-16(12-10-15)17-7-4-5-8-18(17)21-26-29-30-27-21/h4-5,7-12H,3,6,13H2,1-2H3,(H,28,32)(H,26,27,29,30)

SMILES Code: O=C1NN2C(C)=NC(CCC)=C(CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3)C2=N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 426.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Xu Y, Menon V, Jugdutt BI. Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-receptor expression and IP3 receptor and PKCepsilon proteins. J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2):184-95. PubMed PMID: 11967812.

2: Moudgil R, Xu Y, Menon V, Jugdutt BI. Effect of chronic AT(1) receptor antagonism on postischemic functional recovery and AT(1)/AT(2) receptor proteins in isolated working rat hearts. J Cardiovasc Pharmacol Ther. 2001 Apr;6(2):183-8. PubMed PMID: 11509925.

3: Moudgil R, Menon V, Xu Y, Musat-Marcu S, Kumar D, Jugdutt BI. Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in isolated working rat hearts. J Hypertens. 2001 Jun;19(6):1121-9. PubMed PMID: 11403362.

4: O'Brien DW, Xu Y, Menon V, Jugdutt BI. Efficacy of pretreatment with the angiotensin II type 1 receptor blocker UP269-6 and losartan in the dog: effect on hemodynamics and ischemia-reperfusion. J Cardiovasc Pharmacol Ther. 2000 Apr;5(2):129-37. PubMed PMID: 11150392.

5: Soldner A, Spahn-Langguth H, Palm D, Mutschler E. A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites. J Pharm Biomed Anal. 1998 May;17(1):111-24. PubMed PMID: 9608433.

6: Plusquellec Y, Arnaud R, Saivin S, Shepard TA, Carrie I, Hermann P, Souhait J, Houin G. Enterohepatic recirculation of the new antihypertensive drug UP 269-6 in humans. A possible model to account for multiple plasma peaks. Arzneimittelforschung. 1998 Feb;48(2):138-44. PubMed PMID: 9541723.

7: Villa E, Rábano A, Cazes M, Cloarec A, Ruilope LM, García-Robles R. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Am J Hypertens. 1997 Mar;10(3):275-81. PubMed PMID: 9056684.

8: Virone-Oddos A, Desangle V, Provost D, Cazes M, Caussade F, Cloarec A. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation. Br J Pharmacol. 1997 Feb;120(3):488-94. PubMed PMID: 9031754; PubMed Central PMCID: PMC1564468.

9: Cazes M, Provost D, Versigny A, Cloarec A. In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995 Sep 15;284(1-2):157-70. PubMed PMID: 8549620.

10: McIntyre M, MacFadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL. Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man. J Cardiovasc Pharmacol. 1995 Jun;25(6):994-1000. PubMed PMID: 7564347.

11: Inglessis N, Nussberger J, Hagmann M, Hiesse-Provost O, Insuasty J, Reid J, Ménard J, Brunner HR. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I. J Cardiovasc Pharmacol. 1995 Jun;25(6):986-93. PubMed PMID: 7564346.

12: Caussade F, Virone-Oddos A, Delchambre C, Cazes M, Versigny A, Cloarec A. In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Fundam Clin Pharmacol. 1995;9(2):119-28. PubMed PMID: 7628824.

13: Nicolaï E, Curé G, Goyard J, Kirchner M, Teulon JM, Versigny A, Cazes M, Caussade F, Virone-Oddos A, Cloarec A. Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists. J Med Chem. 1994 Jul 22;37(15):2371-86. PubMed PMID: 8057285.